Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2010  |  Volume : 6  |  Issue : 1  |  Page : 31--35

Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review


Rudolf Weide1, Hubert Koppler1, Lucia Antras2, Michael Smith2, MPH Eva Chang2, Jesse Green3, Neil Wintfeld3, Maureen P Neary4, Mei Sheng Duh2 
1 Praxisklinik für Hämatologie und Onkologie Koblenz, Koblenz, Germany
2 Analysis Group, Inc., Boston, MA, USA
3 Hoffmann-La Roche Inc., Nutley, NJ, USA
4 GlaxoSmithKline, USA

Correspondence Address:
Mei Sheng Duh
Analysis Group, Inc 111 Huntington Avenue, 10th floor Boston, MA 02199
USA

Aims : This retrospective study investigated the rates of renal impairment in patients with multiple myeloma treated with zoledronic acid and ibandronate. Materials and Methods : We retrospectively reviewed medical records in a German oncology clinic, from May 2001 to December 2005. Creatinine measurements were analyzed from baseline (before zoledronic acid or ibandronate treatment) to last evaluation for each patient. A total of 84 patients were included. Results : Zoledronic acid increased the risk of renal impairment by approximately 3-fold compared with ibandronate (renal impairment rates: zoledronic acid 37.7% vs. ibandronate 10.5%, relative risk [RR]=3.6, P=0.0029 serum creatinine [SCr]; 62.3% vs. 23.7%, RR=2.6, P=0.0001 glomerular filtration rate [GFR]). Ibandronate-treated patients switched from zoledronic acid had a significantly higher risk of renal impairment than patients receiving ibandronate monotherapy (zoledronic acid over ibandronate 39.1% vs. ibandronate monotherapy 6.7%, RR= 5.9, P=0.028 [SCr]; 65.2% vs 26.7%, RR=2.4, P=0.022 [GFR]). Multivariate analysis found significantly higher hazard ratios for zoledronic acid over ibandronate (SCr: Cox = 4.38, P=0.01; Andersen-Gill=8.22, P < 0.01; GFR: Cox = 4.31, P < 0.01; Andersen-Gill = 3.71, P < 0.01). Conclusions : Overall, this retrospective study suggests that multiple myeloma patients are more likely to experience renal impairment with zoledronic acid than with ibandronate. The risk of renal impairment increased if patients had received prior therapy with zoledronic acid.


How to cite this article:
Weide R, Koppler H, Antras L, Smith M, Eva Chang M, Green J, Wintfeld N, Neary MP, Duh MS. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review.J Can Res Ther 2010;6:31-35


How to cite this URL:
Weide R, Koppler H, Antras L, Smith M, Eva Chang M, Green J, Wintfeld N, Neary MP, Duh MS. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review. J Can Res Ther [serial online] 2010 [cited 2020 Aug 13 ];6:31-35
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2010;volume=6;issue=1;spage=31;epage=35;aulast=Weide;type=0